Derek Maetzold Sells 18,650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 18,650 shares of Castle Biosciences stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $25.93, for a total value of $483,594.50. Following the completion of the transaction, the insider owned 22,129 shares in the company, valued at $573,804.97. This represents a 45.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Castle Biosciences Trading Down 2.7%

CSTL opened at $25.00 on Friday. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. The firm has a market cap of $743.28 million, a price-to-earnings ratio of -29.41 and a beta of 1.09. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The stock has a fifty day moving average price of $33.22 and a 200-day moving average price of $31.70.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The company had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC purchased a new stake in Castle Biosciences during the 3rd quarter worth approximately $16,105,000. Schroder Investment Management Group increased its stake in Castle Biosciences by 8.6% during the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock valued at $13,198,000 after purchasing an additional 51,483 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Castle Biosciences in the third quarter worth $615,000. Squarepoint Ops LLC raised its holdings in shares of Castle Biosciences by 29.1% in the second quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after buying an additional 28,359 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Castle Biosciences by 364.6% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 54,610 shares of the company’s stock worth $1,115,000 after buying an additional 42,857 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Castle Biosciences from $41.00 to $44.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Lake Street Capital increased their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, January 12th. BTIG Research raised their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Guggenheim lifted their price target on shares of Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, KeyCorp reaffirmed an “overweight” rating and set a $50.00 price target on shares of Castle Biosciences in a research report on Thursday, January 29th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $47.57.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.